News

ReAlta Life Sciences Receives $3.2 Million Grant from Virginia Catalyst to Accelerate Trial for the Treatment of Acute Lung Injury Due to COVID-19

ReAlta Life Sciences has received a $3.2 million grant award from The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), to accelerate the Company’s Phase 1b clinical trial evaluating RLS-0071 for the treatment of acute lung injury (ALI) due to COVID-19. The award, which is granted to Virginia companies to support the acceleration of clinical testing of therapeutic drugs that treat life threating symptoms caused by COVID-19, includes additional funding for the Company’s research partner, Old Dominion University of Norfolk, Virginia, to explore other clinical biomarkers relevant for RLS-0071 treatment of COVID-19 patients.

“COVID-19 remains a persistent and challenging global health emergency, despite the remarkable progress made by many countries with effective vaccination campaigns,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “For those patients that are infected, the medical community still has no effective therapy to treat ALI and the damage that results from the condition. We greatly appreciate the support from The Virginia Catalyst, as well as the leadership exhibited by the Commonwealth of Virginia to marshal the considerable resources of the life sciences community in Virginia to respond to the ongoing need for effective therapeutic options to treat COVID-19.”

The Company’s double-blind, placebo-controlled Phase 1b clinical trial evaluating RLS-0071 for the treatment of ALI due to COVID-19 pneumonia in early respiratory failure will be conducted at multiple participating clinical sites throughout North America and Europe. More information about the trial can be found at Clinicaltrials.gov under #NCT04574869.

Recent News

12/05/2022

Danville organization invests in Blacksburg’s CytoRecovery medical cell sorting company

Danville’s investment might mean a CytoRecovery presence in Danville, such as office operations or an internship at Danville Community College. CytoRecovery’s cell sorting could improve understanding of disease and development of drugs. CytoRecovery, an early-stage company that invented and patented less invasive cell sorting, will be able to bring its cell research platform to market

12/01/2022

Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4

11/16/2022

Alliance for Building Better Medicine Names Joy Polefrone as Executive Director

Joy Polefrone, Ph.D. will Lead the Organization in Its Mission to Create a Reliable Supply of Safe, High-Quality, and Affordable Medicines in the U.S. Richmond/Petersburg– Alliance for Building Better Medicine, a coalition of public and private sector stakeholders in the Richmond-Petersburg region, today announced that it has appointed Joy Marie Polefrone, Ph.D., as the organization’s executive director.